

## **FORM 7**

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: **MariMed Inc.** \_\_\_\_\_ (the "Issuer").

Trading Symbol: **MRMD** \_\_\_\_\_

Number of Outstanding Listed Securities: **379,643,844 common shares** \_\_\_\_\_

Date: **May 1, 2024 (reporting April 2024)** \_\_\_\_\_

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

***Updates about the Issuer's business are available under the Issuer's profile on SEDAR+ at <https://www.sedarplus.ca> and on the Issuer's investors website at <https://ir.marimedinc.com>.***

**On April 8, 2024, the Issuer announced it would be reporting its first quarter 2024 financial results on May 8, 2024 after the markets close. Management will host a conference call on May 9, 2024 at 8:00 a.m. EDT to discuss financial results. A webcast will be available and can be accessed via the Issuer's Investor Relations website at [MariMed Q124 Earnings Webcast](#). A playback of the call will also be made available on the Issuer's Investor Relations website. See press release [here](#).**

**On April 9, 2024, the Issuer announced the closing of its acquisition of the operating assets of Our Community Wellness & Compassionate Care Center, Inc. ("Medleaf") in Prince George's County, Maryland on April 5th. Just prior to closing, the Issuer paid the state's adult-use conversion fee and subsequently received an adult-use license to sell retail cannabis products from the Maryland Cannabis Administration ("MCA"). The acquired dispensary has been closed since July 1st, 2023. The Company expects to reopen the dispensary and begin adult-use retail sales by the end of the second quarter, upon regulatory approvals. This marks the Issuer's second adult-use Thrive Wellness dispensary in Maryland that the company owns. MariMed also owns and operates a Thrive Wellness dispensary in Annapolis and a cultivation and processing facility in Hagerstown. The Issuer plans to continue seeking additional dispensary acquisitions to achieve the maximum of four allowed in the state. See press release [here](#).**

**On April 10, 2024, the Issuer announced marketing partnership with two iconic venues in Boston, the MGM Music Hall Fenway and Citizens House of Blues Boston. This groundbreaking partnership marks Nature's Heritage as the Exclusive Cannabis Sponsor, elevating the brand at highly anticipated shows to connect with millions of passionate music fans throughout the year. See press release [here](#).**

**On April 11, 2024, the Issuer announced the closing of its acquisition of Allgreens Dispensary, LLC on April 9, 2024. The approval of the license transfer by the Illinois Department of Financial & Professional Regulation, and subsequent closing of the acquisition, allows the Issuer to fully consolidate the financial results of the Issuer's Thrive-branded dispensary in Casey, Illinois, which had previously been operated under a Managed Services Agreement. See full details in press release [here](#).**

**On April 30, 2024, the Issuer issued a statement from the CEO and President regarding the impending announcement of the DEA's decision to recategorize cannabis from Schedule I to Schedule III under the Controlled Substances Act. See press release [here](#).**

2. Provide a general overview and discussion of the activities of management.

**Management of the Issuer has been actively involved in managing operations and revenue growth, acquiring talent and exploring and evaluating expansion opportunities.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

***On April 11, 2024, the Issuer announced the closing of its acquisition of Allgreens Dispensary, LLC on April 9, 2024. The approval of the license transfer by the Illinois Department of Financial & Professional Regulation, and subsequent closing of the acquisition, allows the Issuer to fully consolidate the financial results of the Issuer's Thrive-branded dispensary in Casey, Illinois, which had previously been operated under a Managed Services Agreement. See full details in press release [here](#).***

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

***Not applicable.***

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

***Not applicable.***

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

***Not applicable.***

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

***On April 9, 2024, the Issuer announced the closing of its acquisition of the operating assets of Our Community Wellness & Compassionate Care Center, Inc. ("Medleaf") in Prince George's County, Maryland on April 5th. Just prior to closing, the Issuer paid the state's adult-use conversion fee and subsequently received an adult-use license to sell retail cannabis products***

**from the Maryland Cannabis Administration (“MCA”). See press release [here](#).**

8. Describe the acquisition of new customers or loss of customers.

***The Issuer continues to seek customer growth through strategic acquisitions, as well as organically through product expansion, increased product availability, and retail footprint expansion.***

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

***Not applicable.***

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

***Not applicable.***

11. Report on any labour disputes and resolutions of those disputes if applicable.

***Not applicable.***

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

***Not applicable.***

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

***Not applicable.***

14. Provide details of any securities issued and options or warrants granted.

<b>Security</b>	<b>Number Issued</b>	<b>Details of Issuance</b>	<b>Use of Proceeds<sup>(1)</sup></b>

1) *State aggregate proceeds and intended allocation of proceeds.*

15. Provide details of any loans to or by Related Persons.

***Not applicable.***

16. Provide details of any changes in directors, officers or committee members.

***Not applicable.***

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

***The Issuer will continue to develop its business as a multi-state cannabis operator, developing and managing seed to sale state-licensed cannabis facilities. The Issuer believes that its products are a positive trend for the Issuer and its shareholders.***

***[Remainder of page intentionally left blank]***

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: May 1, 2024.

Jon R. Levine  
Name of Director or Senior Officer

/s/ "Jon R. Levine"  
Signature

CEO, President and Interim CFO  
Official Capacity

<i>Issuer Details</i> <b>MariMed Inc.</b>	<i>For Month End</i> <b>April 2024</b>	<i>Date of Report</i> <b>2024/05/01</b>
<i>Issuer Address</i> <b>10 Oceana Way</b>		
<i>City/Province/Postal Code</i> <b>Norwood, Massachusetts 02062</b>	<i>Issuer Fax No.</i> N/A	<i>Issuer Telephone</i> <b>(617) 795-5140</b>
<i>Contact Name</i> <b>Jon R. Levine</b>	<i>Contact Position</i> <b>CEO, President and Interim CFO</b>	<i>Contact Telephone</i> <b>(617) 795-5140</b>
<i>Contact Email Address</i> <a href="mailto:jlevine@marimedinc.com">jlevine@marimedinc.com</a>	<i>Web Site Address</i> <a href="https://marimedinc.com/">https://marimedinc.com/</a>	